# Original Article A meta-analysis of the associations between the Q141K and Q126X ABCG2 gene variants and gout risk

Rui Li<sup>1\*</sup>, Lei Miao<sup>1\*</sup>, Liyan Qin<sup>1</sup>, Yang Xiang<sup>1</sup>, Xiaojin Zhang<sup>2</sup>, Hui Peng<sup>3</sup>, Mailamuguli<sup>1</sup>, Yuping Sun<sup>4</sup>, Hua Yao<sup>2</sup>

<sup>1</sup>School of Public Health, Xinjiang Medical University, Urumqi, Xinjiang, China; <sup>2</sup>The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China; <sup>3</sup>Clinical Laboratory, Traditional Chinese Medical Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China; <sup>4</sup>School of Basic Medical Sciences, Xinjiang Medical University, Urumqi, Xinjiang, China. \*Equal contributors.

Received July 22, 2015; Accepted August 25, 2015; Epub September 1, 2015; Published September 15, 2015

Abstract: Background: Gout is an inflammatory disease in which genetic factors play a role. ABCG2 is a urate transporter, and the Q141K and Q126X variants of ABCG2 have been associated with a risk of developing gout, though previous studies of these associations have been inconsistent. Therefore, we conducted a meta-analysis to explore the relationship between these genetic variants and gout. Methods: We examined 8 electronic literature databases. In total, 9 eligible articles on the associations between the Q141K (rs2231142) and Q126X (rs72552713) variants and gout risk, including 11 case-control studies were selected. We used odds ratios (OR) and 95% confidence intervals (CI) to assess the strength of these relationships in dominant, recessive, and co-dominant models. Results: This study included 6652 participants (2499 gout patients and 4153 controls). The Q141K variant was found to significantly increase the risk of gout in Asians (dominant model: OR=2.64, 95% CI=2.04-3.43, P=0.02 for heterogeneity; recessive model: OR=3.19, 95% CI=2.56-3.97, P=0.28 for heterogeneity; co-dominant model: OR=1.37, 95% CI=1.18-1.59, P=0.09 for heterogeneity) and other populations (dominant model: OR=1.85, 95% CI=1.20-2.85, P<0.0001 for heterogeneity; recessive model: OR=3.78, 95% CI=2.28-6.27, P=0.19 for heterogeneity; co-dominant model: OR=1.48, 95% CI=1.26-1.74, P=0.19 for heterogeneity). The Q126X variant also significantly increased the risk of gout in Asians (dominant model: OR=3.87, 95% CI=2.07-7.24, P=0.06 for heterogeneity). Conclusions: These results suggest associations between the rs2231142 and rs72552713 ABCG2 gene polymorphisms and gout risk, which led to unfavorable outcomes. However, studies with larger sample sizes and homogeneous populations should be performed to confirm these results.

Keywords: Gout, Q141K, Q126X, single nucleotide polymorphism, meta-analysis

#### Introduction

Gout is a recurrent relapsing inflammatory disease, caused by the precipitation of monosodium urate (MSU) crystals in the joints and soft tissues. Gout is characterized by intense pain that typically persists for approximately one week. In recent years, the prevalence and incidence of gout has been increasing. In 2001 [1], the prevalence of gout was only 0.33% in Shanghai. In 2009, Yu-Hong Jia et al. [2] reported an increased prevalence of gout of as high 1.21% in Tangshan. Today, the prevalence of gout has increased to 1.23% [3]. In addition, Edward and colleagues [4] also reviewed the epidemiology of gout and suggested that the disease is becoming more prevalent. As a result of its increasing prevalence, gout has attracted public attention.

Previous studies demonstrate that environmental exposure and genetic factors play important roles in the development of gout. Jennifer et al. [5] demonstrated that body mass index (BMI), total fat mass, serum triglycerides and serum glucose levels were significantly increased in gout patients. Ling-Qin Li [6] found that hyperuricemia, BMI, high triglycerides, hypertension, a high purine diet, drinking and smoking increase the risk of gout. Previous studies have demonstrated that genetic variations in solute carrier family 2, member 9 (SLC2A9) [7]; solute carrier family 22, member 11 (SLC22A11) [8]; solute carrier family 17, member 1 (SLC17A1)



Figure 1. Flow diagram of study selection for meta-analysis.

[9]; coding for PDZ domain containing 1 (PDK-Z1) [10] and ATP-binding cassette, subfamily G, member 2 (ABCG2) [11] might increase the risk of gout.

ABCG2 is a urate transporter that excretes uric acid [12]. According to gene sequencing analysis, ABCG2 contains more than 80 different single-nucleotide polymorphism (SNP) loci. Among these, Q141K and Q126X are the most commonly studied. SNP rs2231142, also referred to as C421A or O141K in ABCG2, is located in exon 5 [10] and substitutes glutamic acid for diaminocaproic acid. Previous studies have reported a relationship between rs22-31142 and gout. SNP rs72552713, also referred to as C376T or Q126X in ABCG2, has also been shown to play a role in gout. However, due to small sample sizes and data quality, inconsistent results have been reported. To address these issues, we performed a metaanalysis to explore the roles of rs2231142 and rs72552713 in gout.

# Methods

# Search strategy

We searched for published articles in eight electronic literature databases (Chaoxing Medalink, Wangfang Data, Weipu, Chinese Biomedical Literature Service System, China National Knowledge Infrastructure (CNKI), Chinese Science Citation Database (CSCD), Ebsco Science Direct and Pubmed). No limit was imposed on publication dates, and the last search update was performed on May 30, 2015. The literature search was performed in English and Chinese using the following primary key words: gout, ABCG2, C421A, Q141K, rs2231142, C376T, Q126X, and rs72552713.

## Table 1. Characteristics of the included studies (Q141K)

First author (Ref.)	Year	Ethnicity/country	Diagnostic standard	Study	Sample size	HWE	Genotype distribution (case/control)			Genotype frequency (case/control)		
				design	(case/control)	p-value	CC	CA	AA	CC (%)	CA (%)	AA (%)
Wang Qiong [17]	2014	Asians China	ACR preliminary diagnostic criteria for acute gout (1977)	Case-control	185/311	Yes	64/157	86/126	35/28	34.6/50.5	46.5/40.5	18.9/9.0
Zhang Xin-Lei [28]	2014	Asians China	ACR preliminary diagnostic criteria for acute gout (1977)	Case-control	147/321	Yes	30/167	79/134	38/20	20.4/52.0	53.7/41.7	25.9/6.2
Li Fa-Gui [12]	2011	Asians China	ACR preliminary diagnostic criteria for acute gout (1977)	Case-control	200/235	Yes	64/103	91/112	45/20	32.0/43.8	45.5/47.7	22.5/8.5
Amanda 1 [25]	2010	Maori New Zealand	ACR preliminary diagnostic criteria for acute gout (1977)	Case-control	185/215	Yes	142/172	34/39	2/1	79.8/81.1	19.1/18.4	1.1/0.5
Amanda 2 [25]	2010	Pacific Islander New Zealand	ACR preliminary diagnostic criteria for acute gout (1977)	Case-control	173/109	Yes	58/69	78/36	37/4	33.5/63.3	45.1/33.0	21.4/3.7
Amanda 3 [25]	2010	Caucasian New Zealand	ACR preliminary diagnostic criteria for acute gout (1977)	Case-control	214/562	Yes	122/425	76/125	13/8	57.8/76.2	36.0/22.4	6.2/1.4
Danqiu Zhou [36]	2014	Asians China	ACR preliminary diagnostic criteria for acute gout (1977)	Case-control	352/350	Yes	87/167	181/150	84/33	24.7/47.7	51.4/42.9	23.9/9.4
Klaus [32]	2009	Caucasian German	ACR preliminary diagnostic criteria for acute gout (1977)	Case-control	677/1552	Yes	500/1241	168/299	9/12	73.9/80.0	24.8/19.2	1.3/0.8
Zhang Xiu-Juan [36]	2012	Asians China	ARA diagnostic criteria for acute gout (1997)	Case-control	110/236	Yes	35/120	55/96	20/20	31.8/50.8	50.0/40.7	18.2/8.5
You Yu-Quan [39]	2013	Asians China	ACR preliminary diagnostic criteria for acute gout (1977)	Case-control	154/160	Yes	48/98	78/49	28/13	31.2/60.3	50.6/30.6	18.2/8.1
Ye De-Shao [62]	2012	Asians China	ACR preliminary diagnostic criteria for acute gout (1977)	Case-control	102/102	Yes	23/53	42/40	37/9	22.5/52.0	41.2/39.2	36.3/8.8

## Table 2. Characteristics of the included studies (Q126X)

First author (Ref.)	Year	Ethnicity/ country	Diagnostic standard	Study	Sample size	HWE	Genotype distribution (case/control)			Genotype frequency (case/control)		
				design	(case/control)	p-value	CC	CT	TT	CC (%)	CT (%)	TT (%)
Zhang Xin-Lei [28]	2014	Asians China	ACR preliminary diagnostic criteria for acute gout (1977)	Case-control	136/321	Yes	127/320	9/1	0/0	93.4/99.7	6.6/0.3	0/0
Danqiu Zhou [36]	2014	Asians China	ACR preliminary diagnostic criteria for acute gout (1977)	Case-control	352/350	Yes	319/338	33/12	0/0	90.6/96.6	9.4/3.4	0/0

А	CA+AA	1	CC			Odds Ratio	Odds Ratio
Study or Subgroup	Events	Tota	Events	Tota	Weight	M-H, Random, 95% C	M-H, Random, 95% Cl
Amanda 1 2010	36	76	142	314	8.2%	1.09 [0.66, 1.80]	+-
Amanda 2 2010	115	155	58	127	8.2%	3.42 [2.07, 5.65]	
Amanda 3 2010	89	222	122	547	10.0%	2.33 [1.67, 3.26]	-
Dangiu Zhou 2014	265	448	87	254	10.2%	2.78 [2.02, 3.83]	-
Klaus 2009	177	488	500	1741	11.2%	1.41 [1.14, 1.75]	-
Li Fa-Gui 2011	136	268	64	167	9.4%	1.66 [1.12, 2.46]	
Wang Qiong 2014	121	275	64	221	9.6%	1.93 [1.32, 2.81]	
Ye De-Shao 2012	79	128	23	76	7.2%	3.72 [2.03, 6.81]	· · · · ·
You Yu-Quan 2013	106	168	48	146	8.6%	3 49 [2 19 5 56]	-
Zhang Xin-Lei 2014	117	271	30	197	8.7%	4 23 [2 68 6 68]	
Zhang Xiu-Juan 2012	75	191	35	155	8.5%	2 22 [1 38 3 57]	
Linnig/the obtain 2012					0.070	2.22 [1.00, 0.01]	
Total (95% CI)	2	2690		3945	100.0%	2.32 [1.80, 2.99]	•
Total events	1316		1173				
Heterogeneity: Tau <sup>2</sup> = 0.	14; Chi <sup>2</sup> =	45.61.	df = 10 (f	< 0.00	0001); I <sup>2</sup> =	78%	
Test for overall effect: Z	= 6.53 (P <	< 0.000	)01)				0.01 0.1 1 10 100
			,				Favours (CA+AA) Favours (CC)
В	AA		CA+	CC		Odds Ratio	Odds Ratio
Study or Subaroup	Events	Tota	Events	Total	Weight	M-H. Fixed. 95% CI	M-H. Fixed, 95% Cl
Amanda 1 2010	2	3	176	387	0.8%	2 40 0 22 26 66	
Amanda 2 2010	27	/1	136	241	3.6%	7 14 [2 47 20.67]	
Amanda 2 2010	12	21	100	7.40	2.0%	A 51 [1 0A 11 05]	
Dongiu Zhou 2014	13	117	190	7 40 5 05	3.0%	4.01 [1.04, 11.00]	-
Dangiu Zhou 2014	84	117	208	2000	23.3%	3.01 [1.95, 4.65]	
Klaus 2009	9	21	668	2208	0.0%	1.73 [0.73, 4.12]	
Li Fa-Gui 2011	45	65	155	370	13.2%	3.12 [1.77, 5.50]	
Wang Qiong 2014	35	63	150	433	15.6%	2.36 [1.38, 4.03]	
Ye De-Shao 2012	37	46	65	158	5.3%	5.88 [2.66, 13.02]	
You Yu-Quan 2013	28	41	126	273	9.6%	2.51 [1.25, 5.06]	
Zhang Xin-Lei 2014	38	58	109	410	8.6%	5.25 [2.93, 9.41]	
Zhang Xiu-Juan 2012	20	40	90	306	9.6%	2.40 [1.23, 4.68]	
Total (95% CI)		516		6119	100.0%	3.28 [2.68, 4.00]	•
Total events	348		2141				
Heterogeneity: Chi <sup>2</sup> = 1	2 29 df= 1	10 (P =	: 0 27)· P	= 19%			
Test for overall effect: 7	= 11 60 (F	P < 0 0	0.011	0%			0.01 0.1 1 10 100
			,				Favours (AA) Favours (CA+CC)
С	CA		AA+	22		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Tota	Events	Tota	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% Cl
Amanda 1 2010	34	73	144	317	5.4%	1.05 [0.63, 1.74]	+-
Amanda 2 2010	78	114	95	168	4.6%	1.66 [1.01, 2.74]	
Amanda 3 2010	76	201	135	568	8.3%	1.95 [1.38, 2.75]	-
Dangiu Zhou 2014	181	331	171	371	13.8%	1 41 [1 05 1 90]	-
Vigue 2009	169	467	500	1762	25.9%	1 29 [1 1 2 1 72]	-
Li Eo Gui 2011	01	202	100	222	10.6%	0.0210.62.1.241	
Li Fa-Gui 2011	31	203	109	204	0.5%	0.92 [0.03, 1.34]	L
Wang Glong 2014	80	212	99	284	9.5%	1.28 [0.88, 1.84]	
Yeu Vu Oran 2012	42	82	60	122	4.4%	1.08 [0.62, 1.90]	[
You Yu-Quan 2013	/8	127	76	187	4.5%	2.32 [1.47, 3.69]	
Zhang Xin-Lei 2014	79	213	68	255	7.4%	1.62 [1.09, 2.40]	
Zhang Xiu-Juan 2012	55	151	55	195	5.8%	1.46 [0.93, 2.30]	
Total (05% CI)		2474		1464	100.04/	4 43 14 37 4 501	4
Total (95% CI)		21/4		4401	100.0%	1.42 [1.27, 1.58]	1
lotal events	968		1521				
Heterogeneity: $Chi^2 = 1$	6.27, df = 1	10 (P =	= 0.09); l <sup>*</sup>	= 39%			0.01 0.1 1 10 100
Fest for overall effect: Z	. = 6.27 (P	< 0.00	JUU1)				Favours (CA) Favours (AA+CC)

**Figure 2.** Forest plot of the associations between the Q141K variant and gout risk using the A: Dominant model (CC compared to AC+AA), B: Recessive model (AA compared to CC+AC), and C: Co-dominant model (AC compared to CC+AA).

The following index terms were used: gout and ABCG2, gout and C421A, gout and Q141K, gout and rs2231142, gout and C376T, gout and Q126X, and gout and rs72552713.

#### Selection criteria

In this meta-analysis, we established the following inclusion criteria: (1) the publication

	CA+AA	cc	cc		Odds Ratio	Odds Ratio				
Study or Subgroup	Events T	otal Events	Tota	Weight	M-H, Random, 95% C	M-H, Random, 95% Cl				
7.1.1 Asians										
Danqiu Zhou 2014	265	448 87	254	10.2%	2.78 [2.02, 3.83]	-				
Li Fa-Gui 2011	136	268 64	167	9.4%	1.66 [1.12, 2.46]					
Wang Qiong 2014	121	275 64	221	9.6%	1.93 [1.32, 2.81]	-				
Ye De-Shao 2012	79	128 23	76	7.2%	3.72 [2.03, 6.81]					
You Yu-Quan 2013	106	168 48	146	8.6%	3.49 [2.19, 5.56]					
Zhang Xin-Lei 2014	117	271 30	197	8.7%	4.23 [2.68, 6.68]					
Zhang Xiu-Juan 2012	75	191 35	155	8.5%	2.22 [1.38, 3.57]					
Subtotal (95% CI)	1	749	1216	62.3%	2.64 [2.04, 3.43]	•				
Total events	899	351								
Heterogeneity: Tau <sup>2</sup> = 0	.07; Chi <sup>2</sup> = 1	5.27, df = 6 (	P = 0.02	2); I <sup>2</sup> = 61 9	6					
Test for overall effect: Z	= 7.37 (P <	0.00001)								
7.1.2 Maori										
Amanda 1 2010	36	76 142	314	8.2%	1.09 [0.66, 1.80]	+				
Subtotal (95% CI)		76	314	8.2%	1.09 [0.66, 1.80]	+				
Total events	36	142								
Heterogeneity: Not appl	icable									
Test for overall effect: Z	= 0.34 (P =	0.74)								
7.1.3 Pacific Islander										
Amanda 2 2010	115	155 58	127	8.2%	3.42 [2.07, 5.65]					
Subtotal (95% CI)		155	127	8.2%	3.42 [2.07, 5.65]	•				
Total events	115	58								
Heterogeneity: Not appl	icable									
Test for overall effect: Z	= 4.81 (P <	0.00001)								
7.1.4 Caucasian										
Amanda 3 2010	89	222 122	547	10.0%	2.33 [1.67, 3.26]	-				
Klaus 2009	177	488 500	1741	11.2%	1.41 [1.14, 1.75]	-				
Subtotal (95% CI)		710	2288	21.3%	1.78 [1.09, 2.91]	•				
Total events	266	622								
Heterogeneity: Tau <sup>2</sup> = 0	.10; Chi <sup>2</sup> = 6	6.12, df = 1 (P	= 0.01)	; I <sup>2</sup> = 84%						
Test for overall effect: Z	= 2.31 (P =	0.02)								
						.				
Total (95% CI)	2	690	3945	100.0%	2.32 [1.80, 2.99]	◆				
Total events	1316	1173								
Heterogeneity: Tau <sup>2</sup> = 0	.14; Chi <sup>2</sup> = 4	15.61, df = 10	(P < 0.0	00001); I <sup>z</sup> :	= 78%					
Test for overall effect: Z	= 6.53 (P <	0.00001)				o.or o.r r 10 100				
Test for subgroup differences: Chi <sup>2</sup> = 13.04, df = 3 (P = 0.005), l <sup>2</sup> = 77.0% Favours experimental Favours control										

Figure 3. Forest plot describing ethnicity in the dominant model (Q141K).

must be a genetic connectedness study regarding gout and an ABCG2 gene polymorphism; (2) the diagnostic criteria [13] must adhere to the American College of Rheumatology (ACR) preliminary diagnostic criteria for acute gout; (3) the publication must be a case-control study; (4) the participants must not have serious diseases other than gout; (5) the cases and controls must include specific genotype distribution data; (6) the genotype distribution of the control group must satisfy Hardy-Weinberg equilibrium (HWE); and (7) if a study contained more than one more sample, each sample was used for this meta-analysis.

#### Quality assessment

Two authors selected studies based on the selection criteria described. Disagreements

were resolved by consulting a third author. If more than one article described the same study, we selected the best article and described those with incomplete data. Then, we performed a quality assessment. The assessment criteria were based on the STREGA (STrengthening the Reporting of Genetic Association studies) principle [14], which consists of six requirements. If the included studies fulfilled three or more of those requirements, they were considered to be of good quality. Fortunately, the quality of the included studies was high, and we were able to collect the following data from each study: the first author's name, publication year, country, ethnicity, diagnostic standard of gout, study design, total number of cases and controls, HWE P-value, genotype distribution and geno-

Int J Clin Exp Pathol 2015;8(9):9812-9823

	AA	CA+CC			Odds Ratio	Odds Ratio				
Study or Subgroup	Events	Tota	Events	Tota	Weight	M-H, Fixed, 95% (	CI M-H, Fixed, 95% CI			
8.1.1 Asians										
Danqiu Zhou 2014	84	117	268	585	23.3%	3.01 [1.95, 4.65	] –			
Li Fa-Gui 2011	45	65	155	370	13.2%	3.12 [1.77, 5.50	g   <del>-</del>			
Wang Qiong 2014	35	63	150	433	15.6%	2.36 [1.38, 4.03	g   <del></del> -			
Ye De-Shao 2012	37	46	65	158	5.3%	5.88 [2.66, 13.02	1			
You Yu-Quan 2013	28	41	126	273	9.6%	2.51 [1.25, 5.06	1			
Zhang Xin-Lei 2014	38	58	109	410	8.6%	5.25 [2.93, 9.41	]			
Zhang Xiu-Juan 2012	20	40	90	306	9.6%	2.40 [1.23, 4.68	1			
Subtotal (95% CI)		430		2535	85.2%	3.19 [2.56, 3.97]	」			
Total events	287		963							
Heterogeneity: Chi <sup>2</sup> = 7.9	51, df = 6	(P = 0.	28); l² = 2	20%						
Test for overall effect: Z	= 10.40 (	P < 0.0	0001)							
8.1.2 Maori										
Amanda 1 2010	2	3	176	387	0.8%	2.40 [0.22, 26.66				
Subtotal (95% CI)		3		387	0.8%	2.40 [0.22, 26.66]				
Total events	2		176							
Heterogeneity: Not appli	icable									
Test for overall effect: Z	= 0.71 (P	= 0.48	)							
8.1.3 Pacific Islander										
Amanda 2 2010	37	41	136	241	3.6%	7.14 [2.47, 20.67				
Subtotal (95% CI)		41		241	3.6%	7.14 [2.47, 20.67]				
Total events	37		136							
Heterogeneity: Not appli	icable									
Test for overall effect: Z	= 3.63 (P	= 0.00	03)							
8.1.4 Caucasian										
Amanda 3 2010	13	21	198	748	3.8%	4.51 [1.84, 11.05	]			
Klaus 2009	9	21	668	2208	6.6%	1.73 (0.73, 4.12				
Subtotal (95% CI)		42		2956	10.4%	2.74 [1.49, 5.05]	」			
Total events	22		866							
Heterogeneity: Chi <sup>2</sup> = 2.3	27, df = 1	(P = 0.	13); I² = 5	56%						
Test for overall effect: Z	= 3.24 (P	= 0.00	1)							
Total (95% CI)		516		6119	100.0%	3.28 [2.68, 4.00]	」			
Total events	348		2141							
Heterogeneity: Chi <sup>2</sup> = 12	2.29, df =	10 (P =	0.27); l²:	= 19%						
Test for overall effect: Z	= 11.60 (	P < 0.0	0001)				Eavours experimental Eavours control			
Test for subgroup differences: Chi <sup>2</sup> = 2.49. df = 3 (P = 0.48), I <sup>2</sup> = 0%										

Figure 4. Forest plot describing ethnicity in the recessive model (Q141K).

type frequencies. These data were organized into two tables for analysis.

#### Statistical analysis

We used Review Manager 5.1 software (The Cochrane Collaboration, Oxford, UK) and Stata software (version 11.0) to perform statistical analyses. Associations between gout susceptibility and the rs2231142 and rs72552713 ABCG2 gene polymorphisms were indicated by the odds ratio (OR) and the corresponding 95% confidence interval (Cl). Each relationship was assessed in a dominant model (Q141K: CC compared to AC+AA; Q126X: CC compared to CT+TT), a recessive model (Q141K: AA com-

pared to CC+AC), and a co-dominant model (Q141K: AC compared to CC+AA). We used the  $I^2$  statistic to evaluate heterogeneity between studies, and a fixed effects model (FEM) to calculate the pooled OR and 95% CI if the P-value was greater than 0.05, which indicated no heterogeneity. If heterogeneity was observed, we used a random effects model (REM) to combine eligible data. We examined significant pooled ORs using the Z statistic. To guarantee the stability of the results, we implemented a sensitivity analysis by the sequential removal of individual studies. Publication bias was assessed using funnel plots with Begg's test and Egger's test, in which P>0.05 indicated no publication bias.

	CA	AA+CC			Odds Ratio	Odds	Ratio			
Study or Subgroup	Events	Tota	Events	Tota	Weight	M-H, Fixed, 95% C	M-H, Fixe	d, 95% Cl		
9.1.1 Asians										
Danqiu Zhou 2014	181	331	171	371	13.8%	1.41 [1.05, 1.90]		+		
Li Fa-Gui 2011	91	203	109	232	10.6%	0.92 [0.63, 1.34]	-+	-		
Wang Qiong 2014	86	212	99	284	9.5%	1.28 [0.88, 1.84]	†	-		
Ye De-Shao 2012	42	82	60	122	4.4%	1.08 [0.62, 1.90]	-	_		
You Yu-Quan 2013	78	127	76	187	4.5%	2.32 [1.47, 3.69]				
Zhang Xin-Lei 2014	79	213	68	255	7.4%	1.62 [1.09, 2.40]	· · · · · · · · · · · · · · · · · · ·	-		
Zhang Xiu-Juan 2012	55	151	55	195	5.8%	1.46 [0.93, 2.30]	t	<u>.</u>		
Subtotal (95% CI)		1319		1646	55.9%	1.37 [1.18, 1.59]		<b>+</b>		
Total events	612		638							
Heterogeneity: Chi <sup>2</sup> = 11	.01, df=	6 (P = 0	0.09); I <sup>2</sup> =	46%						
Test for overall effect: Z	= 4.19 (P	< 0.00	01)							
9.1.2 Maori										
Amanda 1 2010	34	73	144	317	5.4%	1.05 [0.63, 1.74]	-	_		
Subtotal (95% CI)		73		317	5.4%	1.05 [0.63, 1.74]		▶		
Total events	34		144							
Heterogeneity: Not appli	cable									
Test for overall effect: Z	= 0.18 (P	= 0.86)	)							
9.1.3 Pacific Islander										
Amanda 2 2010	78	114	95	168	4.6%	1.66 [1.01, 2.74]	ľ	-		
Subtotal (95% CI)		114		168	4.6%	1.66 [1.01, 2.74]	ľ	•		
Total events	78		95							
Heterogeneity: Not appli	cable									
Test for overall effect: Z	= 2.00 (P	= 0.05;	)							
9.1.4 Caucasian										
Amanda 3 2010	76	201	135	568	8.3%	1.95 [1.38, 2.75]		-		
Klaus 2009	168	467	509	1762	25.8%	1.38 [1.12, 1.72]		•		
Subtotal (95% CI)		668		2330	34.1%	1.52 [1.27, 1.82]		•		
Total events	244		644							
Heterogeneity: Chi <sup>2</sup> = 2.3	75, df = 1	(P = 0.	10); I <sup>2</sup> = 6	64%						
Test for overall effect: Z	= 4.51 (P	< 0.00	001)							
Total (95% CI)		2174		4461	100.0%	1.42 [1.27, 1.58]		•		
Total events	968		1521							
Heterogeneity: Chi <sup>2</sup> = 16	i.27, df=	10 (P =	0.09); l²:	= 39%				10 100		
Test for overall effect: Z	= 6.27 (P	< 0.00	001)			F	avours experimental	Favours control		
Test for subgroup differences; Chi <sup>2</sup> = 2.49, df = 3 (P = 0.48), l <sup>2</sup> = 0% rayours experimental Favours control										

Figure 5. Forest plot describing ethnicity in the co-dominant model (Q141K).

#### Results

#### Search results and study characteristics

In total, 48 records were identified that analyzed the associations between ABCG2 polymorphisms and gout risk. The following studies were initially excluded: 11 review articles, an animal-based study and 4 potentially irrelevant studies. Among the remaining 32 studies, 13 additional articles were also excluded: 7 studies were based on specific examined populations, 4 studies did not show a relationship to gout and 2 studies lacked control groups. Thus, 19 total case-control publications were ultimately used. An addition 5 studies was excluded from our meta-analysis due to the absence of genotype frequencies, and 4 pairs of studies were published using the same data, leading us to exclude those 4 additional studies. In total, 9 studies were included in our meta-analysis following the exclusion of another meta-analysis article. All of these 9 studies involved the Q141K variant, and only 2 studies referred to the Q126X variant. The study search procedure used is outlined in **Figure 1**.

Of these 9 studies, of the Q141K variant, one study contained data for three different ethnicities; therefore, each of these studies was treated separately. Thus, 11 total study populations were pooled for our analyses. These 11 studies

#### The association between the ABCG2 gene variant and gout risk



Figure 6. Forest plot for the association between the Q126X variant and gout risk using the dominant model (CT+TT compared to CC).



Figure 7. Sensitivity analysis for the association between the Q141K variant and gout risk.



Figure 8. Begg's funnel plot examining the publication bias of studies using the recessive model (Q141K).

included 7 studies from China [15-21], 3 studies from New Zealand [22] and one study from

Germany [23]. A total of 2499 gout patients and 4153 controls were recruited for this analysis from these 11 studies. We extracted the characteristics of these studies, which are summarized in **Tables 1**, **2** of Article 9 on the Q126X variant. These characteristics were derived from 499 gout patients and 671 controls, and are summarized in **Table 2**.

#### Meta-analysis

A significant association was found between the rs2231142 polymorphism and gout risk in the dominant model (OR=2.32, 95% CI=1.80-2.99, P<0.0001 for heterogeneity), the recessive model (OR=3.28, 95% CI=2.68-4.00, P=0.27 for heterogeneity) and the co-dominant model (OR=1.42, 95% CI=1.27-1.58, P=0.09 for heterogeneity) (Figure 2). Subgroup analysis by ethnicity also revealed significant associations for both Asians (dominant model: OR=2.64, 95% CI=2.04-3.43, P=0.02 for heterogeneity; recessive model: OR=3.19, 95% CI=2.56-3.97, P=0.28 for heterogeneity; co-dominant model: OR=1.37, 95% CI=1.18-1.59, P=0.09 for heterogeneity) and other populations (dominant model: OR=1.85,

95% CI=1.20-2.85, P<0.0001 for heterogeneity; recessive model: OR=3.78, 95% CI=2.286.27, P=0.19 for heterogeneity; co-dominant model: OR=1.48, 95% CI=1.26-1.74, P=0.19 for heterogeneity) (**Figures 3-5**). Our results also demonstrated that the rs72552713 polymorphism can increase the risk of gout in the dominant model: OR=3.87, 95% CI=2.07-7.24, P=0.06 for heterogeneity (**Figure 6**).

## Sensitivity analysis and publication bias

To ensure the stability of our results and given the heterogeneity among studies, we performed a sensitivity analysis by removing studies independently. We did not identify any study that significantly influenced the pooled ORs, indicating that the overall OR was stable (Figure 7). We used funnel plots with Begg's and Egger's tests to detect publication bias. The funnel plot was nearly symmetrical, and the Begg's test (dominant model: P=0.586; recessive model: P=0.484; co-dominant model: P=0.815) and Egger's test (dominant model: P=0.060, 95% CI=-0.203-8.08; recessive model: P=0.642, 95% CI=-2.70-4.16; co-dominant model: P=0.998, 95% CI=-3.23-3.24) did not reveal significant publication bias (Figure 8).

# Discussion

Subsequent to the development of genetic technologies, numerous studies examining the association between ABCG2 polymorphisms and gout risk have been reported. Among the ABCG2 polymorphisms, Q141K and Q126X are the most commonly studied. Nevertheless, the role of the Q141K variant in gout risk and the potential for the Q126X variant to increase gout risk are controversial. Lili Zhang et al. [24] demonstrated that rs2231142 is significantly associated with gout in Europeans, Americans, African Americans and Mexican Americans. Hirotaka et al. [25], Kazumasa et al. [11] and Xiaofei Lv [26] also showed that the Q141K variant increases the risk of gout. However, Amanda et al. [22] reported no association of rs2231142 with gout in Maori samples. Until now, there has been no meta-analysis demonstrating the role of Q126X in gout. To address these discrepancies, we performed a metaanalysis to explore the relationships between rs2231142 and rs72552713 and gout, and we conducted a subgroup analysis to identify racial differences in rs2231142.

In our meta-analysis, we identified 11 studies involving 4 ethnicities (Asians, Maori, Pacific Islanders and Caucasians) from 3 countries (China, New Zealand and Germany) and including a total of 6652 participants (2499 gout patients and 4153 controls). Our results suggested that the Q141K variant results in increased gout risk in dominant, recessive, and co-dominant models, and in subgroup analyses, Q126X also increased gout risk in a dominant model. However, heterogeneity had a significant effect on both the dominant model and rs2231142 subgroup analysis. This effect might be explained by confounders such as age, gender and inscrutable environmental factors. Previous studies have demonstrated that gout might be more prevalent in men [27] and postmenopausal women [28]. However, because these data were not included in certain studies we analyzed, we did not estimate the adjusted OR. Gene-environment interactions might also play a significant role in gout risk, which represents a limitation of our meta-analysis.

Ethnic differences are always mentioned by researchers not only in discussions of gout [29] but also in the association between the Q141K polymorphism and gout risk [24, 30]. In our meta-analysis, we performed a subgroup analysis based on ethnicity. From this subgroup analysis, we found that regardless of race, the Q141K variant increases the risk of gout. The data indicate that rs2231142 enhances the risk of gout particularly in Pacific Islanders, for whom the OR reached 3.42. However, with respect to the Maori, although the OR revealed a relationship with gout and a tendency toward unfavorable outcomes, the association was not significant as the 95% CI (0.66-1.80) exceeded 1. However, these results might be explained by the critical factor of quantity. Our meta-analysis only included one study of Maori people, one of Pacific Islanders and two of Caucasians: therefore, there might be inconsistencies in our analysis related to sample size. Resolving this issue would require further large-scale analyses.

Gout is caused by hyperuricemia, which manifests as high serum uric acid (SUA) in *vivo*. Previous studies [12] have demonstrated that ABCG2 is a urate transporter and there is a significant association between hyperuricemia and gout. Hirotaka and colleagues [31, 32] divided samples into 4 groups according to ABCG2 function ( $\leq 1/4$  function, 1/2 function, 3/4 function, and full function) and reported that ABCG2 dysfunction increases gout risk, especially in the group with the lowest ABCG2 function. Abbas et al. [12] found that SLC2A9 and SLC17A3 also increase uric acid concentration and gout risk. Therefore, we should consider gene-gene interactions and linkage disequilibrium to validate our results, the lack of which is a limitation of the current meta-analysis. This meta-analysis did have certain advantages. We identified 9 articles describing 11 studies, ensured the inclusion of an adequate sample size to validate the relationship between the rs2231142 polymorphism and gout risk, and demonstrated the association between rs72552713 polymorphism and gout risk.

## Conclusion

Our results suggest that the rs2231142 ABCG2 polymorphism is associated with gout not only in Asians but also in other populations. The rs72552713 ABCG2 polymorphism also plays a role in gout in Asians. Our evidence revealed that Q141K and Q126X are risk factors for the development of gout. Heterogeneity in our model and subgroup analyses and certain limitations of this meta-analysis suggest that additional investigations with large sample sizes using well-designed methods and more homogeneous populations should be performed.

## Acknowledgements

This study was supported by the National Natural Science Foundation of China (No. 81460153). The authors thank Yunkai Wang for advice on modifying the meta-analysis and Le Zhang for advice on data analysis.

#### Disclosure of conflict of interest

None.

## Abbreviations

ABCG2, ATP-binding cassette, subfamily G, member 2; MSU, monosodium urate; SUA, serum uric acid; SLC2A9, solute carrier family 2, member 9; SLC22A11, solute carrier family 22, member 11; SLC17A1, solute carrier family 17, member 1; PDKZ1, coding for PDZ domain containing 1; SNP, single-nucleotide polymorphism; ACR, American College of Rheumatology; HWE, Hardy-Weinberg equilibrium; OR, odds ratio; CI, confidence interval; FEM, fixed effects model; REM, random effects model.

Address correspondence to: Dr. Hua Yao, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China. E-mail: Yaohua01@sina. com

#### References

- [1] Dai SM, Han XH, Shi YQ, et al. Prevalence of rheumatic diseases in Shanghai. Modern Rehabilitation 2001; 5: 42-44.
- [2] Jia YH, Cui LF, Yang WH, et al. Epidemiological survey on morbidity of hyperuricemia and gout in Tangshan mining district. Chin J Coal Industry Med 2009; 12: 1933-1935.
- [3] Zhang P, Zhang L, Wang CH, et al. Investigation of hyperuricemia and gout populations in 30year old in Xingtai. Prac Prev Med 2014; 21: 1010-1012.
- [4] Roddy E, FRCP DM, Choi H, et al. Epidemiology of gout. Nat Institutes Health 2014; 40: 155-175.
- [5] Lee J, Lee JY, Lee JH, Jung SM, Suh YS, Koh JH, Kwok SK, Ju JH, Park KS, Park SH. Visceral fat obesity is highly associated with primary gout in a metabolically obese but normal weighted population: a case control study. Arthritis Res Ther 2015; 17: 79.
- [6] Li LQ, Qing YF, Zhou C, et al. Logistic regression analysis on clinical features and related risk factors of primary gout in the northeastern area of China. Shangdong Med 2014; 54: 13-15.
- [7] Li C, Chu N, Wang B, Wang J, Luan J, Han L, Meng D, Wang Y, Suo P, Cheng L, Ma X, Miao Z, Liu S. Polymorphisms in the presumptive promoter region of the SLC2A9 gene are associated with gout in a Chinese male population. PLoS One 2012; 7: e24561.
- [8] Flynn TJ, Phipps-Green A, Hollis-Moffatt JE, Merriman ME, Topless R, Montgomery G, Chapman B, Stamp LK, Dalbeth N, Merriman TR. Association analysis of the SLC22A11 (organic anion transporter 4) and SLC22A12 (urate transporter 1) urate transporter locus with gout in New Zealand case-control sample sets reveals multiple ancestral-specific sffects. Arthritis Res Ther 2013; 15: R220.
- [9] Hollis-Moffatt JE, Phipps-Green AJ, Chapman B, Jones GT, van Rij A, Gow PJ, Harrison AA, Highton J, Jones PB, Montgomery GW, Stamp LK, Dalbeth N, Merriman TR. The renal urate transporter SLC17A1 locus: confirmation of as-

sociation with gout. Arthritis Res Ther 2012; 14: R92.

- [10] Yang Q, Köttgen A, Dehghan A, Smith AV, Glazer NL, Chen MH, Chasman DI, Aspelund T, Eiriksdottir G, Harris TB, Launer L, Nalls M, Hernandez D, Arking DE, Boerwinkle E, Grove ML, Li M, Linda Kao WH, Chonchol M, Haritunians T, Li G, Lumley T, Psaty BM, Shlipak M, Hwang SJ, Larson MG, O'Donnell CJ, Upadhyay A, van Duijn CM, Hofman A, Rivadeneira F, Stricker B, Uitterlinden AG, Paré G, Parker AN, Ridker PM, Siscovick DS, Gudnason V, Witteman JC, Fox CS, Coresh J. Multiple genetic loci influence serum urate and their relationship with gout and cardiovascular disease risk factors. Circ Cardiovasc Genet 2010; 3: 523-530.
- [11] Yamagishi K, Tanigawa T, Kitamura A, Köttgen A, Folsom AR, Iso H; CIRCS Investigators. The rs2231142 variant of the ABCG2 gene is associated with uric acid levels and gout among Japanese people. Rheumatology (Oxford) 2010; 49: 1461-1465.
- [12] Dehghan A, Köttgen A, Yang Q, Hwang SJ, Kao WL, Rivadeneira F, Boerwinkle E, Levy D, Hofman A, Astor BC, Benjamin EJ, van Duijn CM, Witteman JC, Coresh J, Fox CS. Association of three genetic loci with uric acid concentration and risk of gout:a genome-wide association study. Lancet 2008; 372: 1953-1961.
- [13] Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yü TF. Preliminary creteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977; 20: 895-900.
- [14] Little J, Higgins JP, Joannidis JP, Moher D, Gagnon F, von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw J, Scheet P, Gwinn M, Williamson RE, Zou GY, Hutchings K, Johnson CY, Tait V, Wiens M, Golding J, van Duijn C, McLaughlin J, Paterson A, Wells G, Fortier I, Freedman M, Zecevic M, King R, Infante-Rivard C, Stewart AF, Birkett N. Strengthening the reporting of genetic association study (STREGA): an extension of the STROBE statement. PLoS Med 2009; 6: e22.
- [15] Wang Q, Wang C, Wang XB, et al. Association between gout and polymorphisms of rs223-1142 in ABCG2 in female Han Chinese. Prog Modern Biomed 2014; 14: 2437-2440.
- [16] Zhang XL. The association between ABCG2 polymoephism and gout and hyperuricemia by establish queue about staff hyperuricemia. Academic Dissertation 2014: 1-70.
- [17] Li FG, Chu Y, Meng DM, Tong YW. Association of ABCG2 gene C421A polymorphism and susceptibility of primary gout in Han Chinese males. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2011; 28: 683-685.

- [18] Zhou D, Liu Y, Zhang X, Gu X, Wang H, Luo X, Zhang J, Zou H, Guan M. Functional polymorphisms of the ABCG2 gene are associated with gout disease in the Chinese Han male population. Int J Mol Sci 2014; 15: 9149-9159.
- [19] Zhang XJ. Association between rs13124007, rs6850166 and rs2231142 polymorhphisms and gout in the Chinese Han male population. Academic Dissertation 2012: 1-38.
- [20] You YQ. Study on relationship between single nucleotide polymorphism of the SLC2A9, SLC17A3, ABCG2 gene genetic susceptibility to gout. Academic Dissertation 2012: 1-46.
- [21] Ye DS. Analysis of gout risk and urate transporter polymorphism in the Chinese Han population. Academic Dissertation 2012: 1-63.
- [22] Phipps-Green AJ, Hollis-Moffatt JE, Dalbeth N, Merriman ME, Topless R, Gow PJ, Harrison AA, Highton J, Jones PB, Stamp LK, Merriman TR. A strong role for the ABCG2 gene in susceptibility to gout in New Zealand Pacific Island and Caucasian, but not Maori, case and control sample sets. Hum Mol Genet 2010; 19: 4813-4819.
- [23] Stark K, Reinhard W, Grassl M, Erdmann J, Schunkert H, Illig T, Hengstenberg C. Common polymorphisms influencing serum uric acid levels contribute to susceptibility to gout, but not to Coronary Artery disease. PLoS One 2009; 4: e7729.
- [24] Zhang L, Spencer KL, Voruganti VS, Jorgensen NW, Fornage M, Best LG, Brown-Gentry KD, Cole SA, Crawford DC, Deelman E, Franceschini N, Gaffo AL, Glenn KR, Heiss G, Jenny NS, Kottgen A, Li Q, Liu K, Matise TC, North KE, Umans JG, Kao WH. Association of functional polymorphism rs2231142 (Q141K) in the ABCG2 gene with serum uric acid and gout in 4 US populations. Am J Epidemiol 2013; 177: 923-932.
- [25] Matsuo H, Tomiyama H, Satake W, Chiba T, Onoue H, Kawamura Y, Nakayama A, Shimizu S, Sakiyama M, Funayama M, Nishioka K, Shimizu T, Kaida K, Kamakura K, Toda T, Hattori N, Shinomiya N. ABCG2 variant has opposing effects on onset ages of Parkinson's disease and gout. Ann Clin Transl Neurol 2015; 2: 302-306.
- [26] Lv X, Zhang Y, Zeng F, Yin A, Ye N, Ouyang H, Feng D, Li D, Ling W, Zhang X. The association between the polymorphism rs2231142 in the ABCG2 gene and gout risk: a meta-analysis. Clin Rheumatol 2014; 33: 1801-1805.
- [27] Cea Soriano L, Rothenbacher D, Choi HK, García Rodríguez LA. Contemporary epidemiology of gout in the UK general population. Arthritis Res Ther 2011; 13: R39.
- [28] Hak AE, Curhan GC, Grodstein F, Choi HK. Menopause, postmenopausal hormone use

and risk of incident gout. Ann Rheum Dis 2010; 69: 1305-1309.

- [29] Maynard JW, McAdams-DeMarco MA, Law A, Kao L, Gelber AC, Coresh J, Baer AN. Racial differences in gout incidence in a populationbased cohort: atherosclerosis risk in communities study. Am J Epidemiol 2013; 179: 576-583.
- [30] Dong Z, Guo S, Yang Y, Wu J, Guan M, Zou H, Jin L, Wang J. Association between ABCG2 Q141K polymorphism and gout risk affected by ethnicity and gender: a systematic review and meta-analysis. Int J Rheum Dis 2015; 18: 382-391.
- [31] Matsuo H, Nakayama A, Sakiyama M, Chiba T, Shimizu S, Kawamura Y, Nakashima H, Nakamura T, Takada Y, Oikawa Y, Takada T, Nakaoka H, Abe J, Inoue H, Wakai K, Kawai S, Guang Y, Nakagawa H, Ito T, Niwa K, Yamamoto K, Sakurai Y, Suzuki H, Hosoya T, Ichida K, Shimizu T, Shinomiya N. ABCG2 dysfunction causes hyperuricemia due to both renal urate underexcretion and renal urate overload. Sci Rep 2014; 4: 3755.
- [32] Matsuo H, Ichida K, Takada T, Nakayama A, Nakashima H, Nakamura T, Kawamura Y, Takada Y, Yamamoto K, Inoue H, Oikawa Y, Naito M, Hishida A, Wakai K, Okada C, Shimizu S, Sakiyama M, Chiba T, Ogata H, Niwa K, Hosoyamada M, Mori A, Hamajima N, Suzuki H, Kanai Y, Sakurai Y, Hosoya T, Shimizu T, Shinomiya N. Common dysfunctional variants in ABCG2 are a major cause of early-onset gout. Sci Rep 2013; 3: 2014.